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Abstract
Background: Neo-adjuvant chemotherapy followed by radical cystectomy with extended pelvic lymph node
dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC).
Despite this aggressive treatment the outcome is poor and ultimately, 30% of the patients with ≥pT3 tumors
develop a pelvic recurrence. We hypothesize that postoperative adjuvant external beam radiotherapy (EBRT) might
prevent local and lymph node recurrence and improve disease free- and overall survival as loco-regional recurrence
is linked to the development of distant metastasis.
Methods: We plan to perform a multicentric prospective phase two study including 76 patients. Eligible patients
are patients with MIBC, treated with radical cystectomy and presenting with ≥1 of the following characteristics:
– Pathological (p)T3 stage + presence of lymphovascular invasion on pathological examination
– pT4 stage
– <10 lymph nodes removed
– positive lymph nodes
– positive surgical margins
Patients will have a 18F–FDG PET-CT to rule out the presence of distant metastasis prior to EBRT. A median dose of
50 Gy in 25 fractions is prescribed to the pelvic lymph node regions with inclusion of the operative bladder bed in
case of a positive surgical margin. Patients with suspected lymph nodes on PET- CT can still be included in the trial,
but a simultaneous integrated boost to 74Gy to the positive lymph nodes will be delivered. Blood and urine
samples will be collected on day-1 and last day of EBRT for evaluation of biomarkers. The primary endpoint is
evaluation of acute ≥Grade 3 intestinal or grade 4 urinary toxicity, in case of a neo-bladder reconstruction, within
12 weeks after EBRT. Secondary endpoints are: assessment of QOL, late RTOG toxicity, local control, disease free
survival and overall survival. Biomarkers in urine and blood will be correlated with secondary survival endpoints.
Discussion: This is a prospective phase 2 trial re-assessing the feasibility of adjuvant radiotherapy in high-risk MIBC.
Trial registration: The Ethics committee of the Ghent University Hospital (EC2014/0630) approved this study
on 31/07/2014.
Trial registration on Clinicaltrials.gov (NCT02397434) on November 19, 2014.
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Background
Muscle invasive bladder cancer (MIBC) is the ninth
most frequently diagnosed cancer and ranks 13th in
terms of causes of death worldwide [1]. The incidence of
bladder cancer increases steadily with age. Due to
improved life expectancy, the number of patients diag-
nosed with MIBC is expected to increase in the future.
A radical cystectomy combined with an extended
pelvic lymph node dissection (ePLND) is considered to
be the treatment of choice. Cisplatin-based neo-adjuvant
chemotherapy improves survival outcomes and is
recommended for patients with cT2-T4a N0–1 M0
MIBC [2, 3]. Despite this multimodality treatment the
outcome did not altered significantly over the last
30 years [4] and remains poor with 5-years overall
survival rates ranging between 50 [5] and 60% [6] to
65% [7]. For patients with ≥pT3 MIBC the 5-year overall
survival even drops to as low as 22% [8]. Others have
reported somewhat better results with a 5-year bladder
cancer specific survival of 31 and 48% for T4 and T3
MIBC patients respectively [6].
Besides the high rate of systemic recurrences, loco-
regional control is equally important. Approximately
30% of patients with ≥pT3 tumors develop a pelvic
recurrence [8–10]. For instance, in a contemporary
monocentric analysis from a high-volume, tertiary center
focusing on 334 pT3–4 pN0–1 MIBC patients, 31% of
patients developed a pelvic recurrence, 34% of which
had loco-regional only failure. Chemotherapy, whether
immediately postoperative (adjuvant) or delayed at time
of recurrence, might improve the outcome of patients
with MIBC as was suggested in a recent meta-analysis
[11]. Unfortunately, these results are based on very
inhomogeneous data. The conclusions of this meta-ana-
lysis are not considered to be robust and it remains unclear
which patients really benefit from it [12]. Generally, neo-
adjuvant chemotherapy is preferred, which does not inter-
fere with this trial. Currently, there are also several trials
already running or being initiated looking at the use of ad-
juvant immunotherapy with MIBC. While this approach
looks promising, eventual adjuvant immunotherapy does
not exclude adjuvant radiotherapy. In fact, there might be
an additional benefit in the combination [13].
The rationale for adjuvant radiotherapy also reflects
that attempts to salvage patients with pelvic failures are
rarely successful [14]. Indeed, 1- and 2-years survival for
patients developing a local recurrence after cystec-
tomy is only 8 and 3% respectively, with a median
survival of <4 months [15]. For patients with lymph
node recurrence prognosis is somewhat better, but
nevertheless still disappointing with reported 1- and
2 years survival of 42 and 11% respectively [15].
Moreover, pelvic recurrences are often debilitating
with pain, lymphedema and venous thrombosis as
known morbidities. If patients with local or lymph
node recurrence are treated with external beam radio-
therapy (EBRT), 1-year survival is significantly improved
from 2% (no EBRT) to 27% [15]. Apparently, improving
loco-regional control can impact survival in MIBC. We
hypothesize that an earlier implementation of pelvic EBRT
i.e. in the immediate postoperative (i.e. adjuvant) setting,
will prevent local and pelvic nodal recurrence and
improve disease free- and overall survival as loco-
regional recurrence is linked to the development of dis-
tant metastasis [16, 17].
Little is known about the timing of EBRT combined
with radical cystectomy in MIBC. Preoperative EBRT
can prevent intra-operative seeding of tumor cells and
sterilizes microscopic extensions in the perivesical
tissues. However, a meta-analysis of six randomized
trials showed no clear benefit for preoperative irradiation
[18]. Adjuvant EBRT also has the advantage of dealing
with microscopic cells along with a better identification
of patients who are really at increased risk of developing
local recurrence based on histological information of the
primary tumor. Already two decennia ago, adjuvant
EBRT was tested in a prospective randomized trial and
resulted in a 20% increase in 5-year disease free survival
(DFS) [19, 20]. These results were supported by a non-
randomized controlled Radiation Therapy Oncology
Group trial [21]. Also in the era of modern surgery it is
suggested that adjuvant radiotherapy improves outcome.
Shariat et al. found that, although a limited number of
patients, adjuvant radiotherapy was independently
associated with lower disease recurrence (HR: 3.3,
95% CI: 2.2–4.9; p < 0.001) and improved disease
specific survival (HR: 2.4, 95% CI: 1.6–3.7; p < 0.001)
while in the same study the impact of adjuvant
chemotherapy on similar outcomes was less clear [6].
Despite those encouraging results, severe intestinal
toxicity rates hampered the enthusiasm to use adju-
vant EBRT, in fact till now [19, 21]. However, the
technology that was used in the above-mentioned trials is
outdated and conclusions concerning toxicity do not apply
to the current technologies such as intensity-modulated
radiotherapy (IMRT) and volumetric arc therapy (VMAT)
and image guided radiotherapy [22–24]. Therefore, it is
reasonable and even desirable to reconsider the use of
adjuvant EBRT in properly selected MIBC patients.
This “proper” selection should be based on clinical,
pathological, radiological and biological predictors for
local and locoregional failure. Well-known clinical and
pathological predictors are T-stage, lymph node status
[6, 25], presence of lymphovascular invasion [6] and
surgical margin status [10].
To select those MIBC patients who will benefit most
from postoperative EBRT it is important to first rule out
distant metastasis. So far, conventional imaging techniques
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fail to detect recurrences or metastasis from bladder
cancer at an early stage. Although only few studies have
evaluated the potential role of 18F–FDG-PET-CT in the
loco-regional staging of patients with MIBC, specificity
and negative predictive values mounts to >90% rendering
it an interesting tool in the staging of MIBC patients,
although its use is currently recommended only within
clinical trials [26]. 18F–FDG-PET-CT has also been studied
in the recurrent setting. Although the evidence is limited it
has been suggested that a good diagnostic performance is
obtained with 18F–FDG-PET-CT in the recurrent setting of
MIBC [27]. By implementing 18F–FDG-PET-CT prior to
the start of adjuvant radiotherapy we aim to exclude
patients with distant metastasis as these patients are less
likely to benefit from this treatment approach.
Additionally, circulating biomarkers can be used to iden-
tify patients who are at increased risk for local and pelvic
nodal relapse for whom this multimodality therapy is pre-
sumed to be most beneficial. Biomarkers will be evaluated
to determine if they can help in selecting those patients
most likely to benefit from adjuvant radiotherapy.
Methods/design
This study is approved by the Ethics committee of the
Ghent University Hospital (EC2014/0630) and is regis-
tered on clinicaltrials.gov (NCT02397434). Patients with
high risk (see below) of developing local or pelvic nodal
recurrence after radical cystectomy with ePLND will be




○ Acute toxicity defined as toxicity occurring
during or within 3 months following adjuvant
EBRT and scored by:
▪ Acute Radiation Therapy Oncology Group
(RTOG) small and large intestine toxicity [28]
and Common toxicity criteria version 4.0
(CTC v4.0) [29]
▪ Acute RTOG [28] and CTC v4.0 [29] bladder
toxicity for patients with a neobladder only
– Secondary endpoints
○ Quality of life (QOL) scoring using the EORTC
QLQ-C30 supplemented with QLQ-BLM30 prior
to, at the end and 1 month after adjuvant EBRT,
then 3-monthly during the first year and
6-monthly up to 2 years.
○ Assessment of quality-adjusted-life-years with
the EuroQol classification system (EQ-5D) [30].
A written consent to use this system was
obtained from the EuroQol Group Foundation.
○ Assessment of erectile function using the
International Index of Erectile Function (IIEF)
questionnaire [31] in males and sexual function
in females [32].
○ Assessment of voiding pattern using the
International prostate Symptom Score (I-PSS)
[33] and International Consultation on
Incontinence Modular Questionnaire Urinary
Incontinence (ICIQ-UI) Short Form [34] for
patients with a neobladder.
○ Late toxicity due to radiotherapy will be scored
using RTOG [28] and CTC v4.0 [29] scoring
systems. Late toxicity is defined as toxicity
lasting more than 3 months after cessation of
adjuvant EBRT, or starting more than 3 months
after the end of adjuvant radiotherapy.
○ Local control rate defined as absence of
recurrence within the pelvis. This will be
evaluated on pelvic CT scans performed on
predefined time-points (see below) or in case of
suspicion of recurrence.
○ DFS defined as survival without evidence of
disease recurrence (neither local recurrence,
recurrence in lymph nodes or distant metastasis)
and is calculated from date of radical cystectomy
till diagnosis of local, regional or distant
recurrence on CT scan at predefined time-points
or in case of suspicion of recurrence.
○ Bladder cancer specific survival calculated from
date of radical cystectomy till death due to MIBC.
○ Overall survival calculated from date of radical
cystectomy till death of any cause.
○ Serum samples and urine samples after
cystectomy will be collected and stored in a
biobank. Biomarkers will be evaluated on all
samples in duplicate and correlated with DFS and
bladder cancer specific survival.
Inclusion criteria
Eligible patients are patients with M0-MIBC, treated
with radical cystectomy and ePLND with ≥1 of the fol-
lowing characteristics:
– pathological (p)T3-MIBC with presence of
lymphovascular invasion on pathological
examination
– pT4 -MIBC
– <10 lymph nodes removed
– presence of pathological positive lymph nodes
– positive surgical margins
and
– WHO performance state 0–2
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– Age ≥ 18 years old
– Willing and able to provide a signed informed
consent
Exclusion criteria
– Presence of distant metastasis at time of inclusion
– Previous pelvic irradiation
– Presence of any psychological, familial, sociological
or geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule
– Presence of a second primary tumour other than
accidental finding of completely removed prostate
cancer, non-melanoma skin tumour or tumour diag-
nosed ≥5 years ago
Evaluation and inclusion
A flow chart presenting the different steps from inclu-
sion until treatment is presented in Fig. 1. EBRT should
start during week 6–12 after radical cystectomy.
Intervention
A 18F–FDG-PET-CT is recommended but not obligatory
within 4–10 weeks after radical cystectomy to rule out
distant metastases.
All patients receive a planning CT on week 5–10 after
radical cystectomy. Planning CT is performed in supine
position with 3 mm CT slice thickness from the lung top
till mid femur.
The target volume comprises the pelvic lymph node
areas at risk in all cases. This stems from the observa-
tion that most recurrences are in the pelvic sidewall
region so that the central pelvis, and the cystectomy bed
in particular, might reasonably be spared treatment
unless margins are involved [8, 11]. The lymph node
regions at risk are the lymph nodes located along the
common, internal and external iliac artery, the lymph
nodes in the obturator fossa and the presacral nodes.
Suspicious lymph nodes on 18F–FDG-PET-CT imaging
are delineated separately. All delineated lymph node
regions at risk are then summed to a structure named as
Lnn. The clinical target volume (CTV)_Lnn is then
Fig. 1 Overview of study flow chart. Abbreviations: p: pathological; EBRT: external beam radiotherapy; RC: radical cystectomy
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created using an isotropic expansion of 2 mm around
the Lnn. The planning target volume (PTV)_Lnn is
created using a 5 mm margin around the CTN_Lnn.
The bladder bed is only included in the radiation field
if there is a positive surgical margin [8, 14]. Pre cystec-
tomy imaging as well as information obtained from the
surgical report and anatomopathological evaluation is
used for delineation of the bladder bed.
A median dose of 50 Gy is prescribed to the pelvic lymph
nodes ± bladder bed and is delivered in 25 fractions, 5
times a week. A simultaneous integrated boost up to 70 Gy
(corresponding to a normalised iso-effective dose of 74 Gy
in 2 Gy fractions calculated with an α/β of 10 [35]) to the
positive lymph nodes, detected on (18F–FDG-PET-)CT, is
prescribed. VMAT is used. The treatment is delivered on a
linear accelerator using 6–18 MV photons and multileaf
collimation [23, 24]. Patient positioning during treatment is
controlled by daily cone beam CT.
Follow up
Patients are followed weekly during therapy, 1 month after
therapy and 3- monthly thereafter. After the end of radio-
therapy and at each follow up visit a standard blood
control (including sedimentation, erythrocytes, leucocytes
(including formula), thrombocytes, creatinine, electrolytes,
liver parameters, alkaline phosphatase) is performed. In
asymptomatic patients imaging (CT thorax/abdomen/
pelvis) will be performed 3–6-monthly after the end of
radiotherapy during the first year and 6-monthly there-




We plan to perform a multicentric prospective phase 2
study in which 76 patients will be enrolled. With this
sample size there is 95% likelihood that no more than
25% ± 10% [21] of the patients will develop severe tox-
icity (i.e. grade ≥ 3 toxicity requiring hospitalization and/
or surgical re-intervention) after adjuvant radiotherapy.
This number takes into account 5% percentage of miss-
ing data.
Data analysis
The primary endpoint is acute toxicity defined as any
toxicity from start of adjuvant EBRT up to 3 months
following adjuvant EBRT.
The incidence of late toxicity will be recorded. Actuar-
ial risk estimates for developing late toxicity will be
calculated using Kaplan Meier analysis.
QOL will be evaluated pre-radiotherapy, at the end of
radiotherapy and 1 month after radiotherapy. Thereafter
a 3 monthly evaluation will be performed during the first
year and 6-monthly up to 2 years after radiotherapy.
DFS, bladder cancer specific survival and overall
survival will also be calculated using Kaplan Meier actu-
arial analysis. Survival times are defined from the date of
radical cystectomy until an event or last follow up.
Discussion
For patients with MIBC neo-adjuvant chemotherapy and
radical surgery is standard of care [3]. Unfortunately the
outcome remains poor for high-risk MIBC patients and the
overall survival hasn’t improved significantly over the past
years. Further efforts to improve the outcome of these pa-
tients are therefore mandatory. Previous trials showed that
adjuvant radiotherapy can improve DFS at the cost of se-
vere toxicity [9–20]. The latter limited the enthusiasm to
propose adjuvant radiotherapy to patients with high-risk
MIBC. In the last decade, major technological advance-
ments in radiotherapy delivery have been realized, resulting
in a better coverage of the target volume while sparing
more normal tissue (mainly small bowel) and in a more
precise delivery of radiation. VMAT is such a technique
that can significantly reduce late toxicity [23, 24]. Further-
more, better insights in the pattern of local relapse, based
on large surgical data [8–10], enable us to tailor and restrict
the radiation field to the area that is at highest risk of devel-
oping recurrence. Based on these observations there is a
renewed interest in reevaluating the place of adjuvant
radiotherapy in those MIBC patients who are at increased
risk of developing disease recurrence [36]. The aim of this
prospective phase 2 trial is to support the hypothesis that
with modern radiotherapy toxicity of adjuvant radiotherapy
after radical cystectomy is acceptable.
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